Mitsubishi UFJ Asset Management’s Candel Therapeutics CADL Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$301K	Buy	+29,236	New	+$221K	﹤0.01%	960

Other funds holding CADL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HFF

Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return

TWM

Tanager Wealth Management Goring On Thames, United Kingdom $1.15B AUM 19.91% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

TGIA

Torrey Growth & Income Advisors Del Mar, California $294M AUM 37.95% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Mitsubishi UFJ Asset Management's CADL Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management opened a new position in Candel Therapeutics (CADL) in Q2 2026: 29,236 shares worth $301K. The stake represents ﹤0.01% of the portfolio and ranks #960 among its holdings.

46 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

Mitsubishi UFJ Asset Management held 29,236 shares of Candel Therapeutics worth $301K as of Q2 2026.
Candel Therapeutics was a new Mitsubishi UFJ Asset Management position in Q2 2026.
Candel Therapeutics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #960 holding.
46 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.